[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100626790":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":18,"responsibleParty":32,"collaborators":10,"id":36,"slug":10,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":39,"acronym":10,"eligibilityCriteria":40,"healthyVolunteers":37,"sex":41,"minAge":42,"maxAge":10,"enrollmentInfo":43,"targetDuration":10,"studyType":46,"phases":10,"briefSummary":47,"conditions":48,"keywords":50,"overallStatus":55,"whyStopped":10,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},{"fullName":5,"class":6},"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Targeted Ivonescimab PET",null,"Noninvasive PET imaging of 89Zr-AK112 for evaluating its expression and distribution in esophageal cancer patients",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Xiao Chen, PH .D","CONTACT","15922970174","xiaochen229@tmmu.edu.cn",[19],{"facility":20,"status":10,"city":21,"state":22,"zip":23,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":10},"Daping Hospital, Army Medical University","Chongqing","Chongqing Municipality","400010","China","CN",{"type":27,"coordinates":28},"Point",[29,30],106.55771,29.56026,{"lat":30,"lon":29},{"type":33,"investigatorFullName":34,"investigatorTitle":35,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Xiao Chen","Director of Nuclear Medicine Department","100626790",false,"NCT07440212","Clinical Study on Noninvasive Evaluation of Ivonescimab Antibody Distribution and Expression in Esophageal Cancer Patients by 89Zr-AK112 PET Imaging","Inclusion Criteria:\n\n* 1\\) Patients aged over 18 years with no gender restriction;\n* 2\\) Patients diagnosed with esophageal cancer;\n* 3\\) Patients eligible for 89Zr-AK112 PET examination;\n* 4\\) Written informed consent signed by the subject or their legal guardian.\n\nExclusion Criteria:\n\n* 1\\) Patients who have received antitumor therapy prior to PET\u002FCT scanning;\n* 2\\) Patients with severe diseases that cannot tolerate PET\u002FCT scanning;\n* 3\\) Alternative subjects with contraindications to PET\u002FCT scanning;\n* 4\\) Radiation exposure exceeding 50 mSv dose in the past year;\n* 5\\) Alternative subjects who underwent major surgery within the past 3 months; those who received experimental drugs or devices (with unclear efficacy or safety) within the past 1 month;\n* 6\\) Alternative subjects with any clinical conditions that the principal investigator of this study considers may cause or pose potential hazards from the investigational product.","ALL","18 Years",{"count":44,"type":45},50,"ESTIMATED","OBSERVATIONAL","As a humanized bispecific antibody targeting PD-1 and VEGF-A, everolizumab exhibits high specificity for binding PD-1 and VEGF-A in vivo. This critical property was systematically validated in a recent molecular imaging study based on positron emission tomography (PET). The study utilized radiolabeled everolizumab to construct an everolizumab PET probe, enabling non-invasive and dynamic monitoring of drug distribution and targeting behavior in living organisms. The results demonstrated that the PET probe exhibited excellent target tissue enrichment in the HCT-116 colorectal cancer xenograft model. In vivo PET imaging revealed a sustained increase in tumor uptake over time, peaking at 48 hours post-administration at 13.73 ± 0.95% ID\u002Fg, indicating strong tumor retention. Blocking experiments (pre-injection of excess everolizumab) significantly reduced tumor uptake to 5.20 ± 0.10% ID\u002Fg (P=0.00011), strongly supporting that its in vivo targeting is mediated by PD-1\u002FVEGF-A-specific interactions rather than nonspecific accumulation. At 48 hours, the tumor-to-muscle signal-to-noise ratio (T\u002FM ratio) reached 15.62, with an outstanding target-to-background ratio explaining the superior efficacy and safety of everolizumab. Furthermore, in vitro distribution studies confirmed that the retention levels of this antibody in non-target organs such as the liver and blood were significantly lower than those in tumor tissues, suggesting favorable pharmacokinetic properties that may reduce associated potential toxicity risks. Histopathological analysis (H\\&E staining) demonstrated no signs of inflammation, necrosis, or other pathological damage in major organs (including the heart, liver, spleen, and kidneys), indicating that evolocimab exhibits good biocompatibility and tolerable safety characteristics.",[49],"Esophagus Cancer",[51,52,53,54],"esophagus cancer","PET","Ivonescimab","PD-1","NOT_YET_RECRUITING","2026-02-23",{"date":58,"type":59},"2026-02-27","ACTUAL",{"date":61,"type":45},"2026-02-01",{"date":63,"type":45},"2027-12-31",{"name":5,"class":6},1]